scholarly journals Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Jingyu Liu ◽  
Jing Li ◽  
Hui Wang ◽  
Yikai Wang ◽  
Qiongzhi He ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Genetic Risk ◽  
Genetic Risk Factors ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Er Positive ◽  
Post Menopause

Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients

2015 ◽  
Vol 152 (1) ◽  
pp. 67-76 ◽  
Author(s):  
Christof Vulsteke ◽  
Alena M. Pfeil ◽  
Charlotte Maggen ◽  
Matthias Schwenkglenks ◽  
Ruth Pettengell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Genetic Risk ◽  
Cardiac Toxicity ◽  
Genetic Risk Factors ◽  
Breast Cancer Patients

A prospective study on genetic risk factors in an unselected sample of breast cancer patients who receive adjuvant radiotherapy

1998 ◽  
Vol 34 ◽  
pp. S118-S119
Author(s):  
C.C. Wárlám-Rodenhuis ◽  
C.H.F. Gimbrère ◽  
R.P. van Helvoirt ◽  
K.E. van der Wiele ◽  
H.F.A. Vasen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Prospective Study ◽  
Cancer Patients ◽  
Genetic Risk ◽  
Adjuvant Radiotherapy ◽  
Genetic Risk Factors ◽  
Breast Cancer Patients ◽  
Unselected Sample ◽  
A Prospective Study

Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 Breast Cancer patients

Breast Cancer ◽  
2006 ◽  
Vol 13 (3) ◽  
pp. 300-307 ◽  
Author(s):  
Mayumi Iwakawa ◽  
Shuhei Noda ◽  
Shigeru Yamada ◽  
Naohito Yamamoto ◽  
Yukimasa Miyazawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Genetic Risk ◽  
Genetic Risk Factors ◽  
Breast Cancer Patients ◽  
Skin Reactions

Clinical and genetic risk factors for the prediction of hepatotoxicity induced by docetaxel, epirubicin and cyclophosphamide regimen in breast cancer patients

2020 ◽  
Author(s):  
Shunmin Huang ◽  
Jing Yang ◽  
Fangmeng Fu ◽  
Chuan Wang ◽  
Xiaoxiong Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Genetic Risk ◽  
Genetic Factors ◽  
Genetic Risk Factors ◽  
Regression Analyses ◽  
Breast Cancer Patients ◽  
Nonalcoholic Fatty Liver ◽  
Increased Risk

Aim: To screen clinical and genetic risk factors and examine their combined effect on docetaxel, epirubicin and cyclophosphamide (TEC) regimen-induced liver injury (TEC-ILI). Patients & methods: We enrolled 396 breast cancer patients, and TEC-ILI-associated factors were screened by logistic regression analyses. Results: SOD2 rs4880 and ABCG2 rs2231142 polymorphisms correlated with an increased risk of TEC-ILI. Multivariate analysis incorporating clinical and genetic factors revealed that ABCC1 rs246221 (CC) and SOD2 rs4880 (AG/GG) increased the risk of TEC-ILI. Patients with at least two risk factors among nonalcoholic fatty liver disease, high low-density lipoproteinemia levels and the rs246221 or rs4880 adverse genotypes exhibited a significantly increased risk of developing TEC-ILI. Conclusion: The combination of clinical and genetic risk factors had higher predictive value for TEC-ILI than the interclinical risk factors alone.

A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS627-TPS627 ◽  
Author(s):  
Elisabeth De Vries ◽  
Clasina Marieke Venema ◽  
Andor W. J. M. Glaudemans ◽  
Lorraine Fitzpatrick ◽  
Dinesh Purandare ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Phase 1 ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Phase 1 Study ◽  
Er Positive
Sign in / Sign up

Export Citation Format

Share Document